NMRA
Income statement / Annual
Last year (2024), Neumora Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Neumora Therapeutics, Inc. Common Stock's net income was -$243.79 M.
See Neumora Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$668,000.00
|
$2.70 M
|
$1.55 M
|
$0.00
|
| Gross Profit |
$0.00
|
-$668,000.00
|
-$2.70 M
|
-$1.55 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$200.93 M
|
$142.72 M
|
$104.75 M
|
$212.78 M
|
$87.13 M
|
| General & Administrative Expenses |
$62.54 M
|
$45.48 M
|
$31.12 M
|
$24.55 M
|
$8.39 M
|
| Selling & Marketing Expenses |
$0.00
|
-$668,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$62.54 M
|
$44.81 M
|
$31.12 M
|
$24.55 M
|
$8.39 M
|
| Other Expenses |
$0.00
|
$0.00
|
$405,000.00
|
$11,000.00
|
-$3.75 M
|
| Operating Expenses |
$263.46 M
|
$187.53 M
|
$135.87 M
|
$237.32 M
|
$95.52 M
|
| Cost And Expenses |
$0.00
|
$188.19 M
|
$135.87 M
|
$237.32 M
|
$95.52 M
|
| Interest Income |
$19.93 M
|
$16.61 M
|
$4.56 M
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$668,000.00
|
$2.70 M
|
$1.55 M
|
$105,000.00
|
| EBITDA |
-$263.46 M |
-$187.53 M |
-$135.28 M |
-$236.79 M |
-$95.41 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$19.86 M
|
-$47.46 M
|
$4.97 M
|
$11,000.00
|
-$3.75 M
|
| Income Before Tax |
-$243.61 M
|
-$235.66 M
|
-$130.90 M
|
-$237.31 M
|
-$99.27 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$178,000.00
|
$268,000.00
|
-$4.56 M
|
$301,442.00
|
-$101,297.00
|
| Net Income |
-$243.79 M
|
-$235.93 M
|
-$130.90 M
|
-$237.31 M
|
-$99.27 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.53 |
-1.49 |
-0.86 |
-1.56 |
-0.65 |
| EPS Diluted |
-1.53 |
-1.49 |
-0.86 |
-1.56 |
-0.65 |
| Weighted Average Shares Out |
$159.38 M
|
$158.83 M
|
$151.95 M
|
$151.95 M
|
$151.95 M
|
| Weighted Average Shares Out Diluted |
$159.38 M
|
$158.83 M
|
$151.95 M
|
$151.95 M
|
$151.95 M
|
| Link |
|
|
|
|
|
